Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma ... ( Celldex also receives approval from...)

HOME >> MEDICINE >> TECHNOLOGY

Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme

Date:12/7/2007

Celldex also receives approval from Health Canada to open clinical sites

and establishes a collaboration with the National Cancer Institute

PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.

In the ACTIVATE phase IIa study, CDX-110 treated GBM patients showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. However, preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, a
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

Post Your Comments:

(Date:5/21/2013)... Calif. , May 21, 2013 RenovoRx ... prestigious 2013 TiE50 "Top Startup" Award at TiEcon 2013, ... innovation, strong management team and quality of entrepreneurial ideas. ... at the Santa Clara Convention ... highly influential list of the most enterprising startup companies ...

(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... image and impressive new product developments at the Special Libraries ... ten years of unerring focus on product literature databases and ... to mark the occasion," said founding director Nigel ... interesting developments of benefit to our clients and what better ...

(Date:5/21/2013)... , May 21, 2013 /PRNewswire-iReach/ -- The 2013 ... NJ has attracted the greatest number of "Emerging" ... President, Mark Alexay . "No ... to attend this year. The show,s still 4 months ... companies. This is a big surprise and great ...

Breaking Medicine Technology:RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3 Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2

[0] RenovoRx Named Winner of 2013 TiE50 "Top Startup"[0] Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia [0] Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show

... Conn., Jan. 7 Alexion,Pharmaceuticals, Inc. (the ... commenced dosing in the AEGIS study, a ... and pharmacology of Soliris(R) (eculizumab),as a treatment ... When fully enrolled, the open-label study, authorized,by ...

... Innocoll, Inc., a privately-held,specialty pharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R) BUPIVACAINE SURGICAL,IMPLANT for the management of ... BUPIVACAINE SURGICAL IMPLANT is a biodegradable and ...

Cached Medicine Technology:Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan 2 Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan 3 Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan 4 Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan 5 Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan 6 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and ... free Community Wellness Fair to educate the public on health ... held on Wednesday, May 22, 2013 from 4:00 pm until ... Old Mallard Creek Road, Charlotte, NC 29262). , ... the Mecklenburg County Department of Social Services are ...

(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...

(Date:5/21/2013)... 2013 Diversity Focus, a non-profit organization ... all residents in the Creative Corridor region, is releasing ... a news conference on Thursday, May 23rd at 10:30 ... in 2008. , The survey is a ... support efforts that attract, nurture and retain people of ...

(Date:5/21/2013)... two proteins, thrombospondin-1 and prosaposin, play in discouraging ... a five-amino acid fragment of prosaposin that significantly ... breast and lung cancer. The findings suggest that ... a variety of cancers. , The study ... Children,s Hospital, Vivek Mittal, PhD, at Weill Cornell ...

(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Vinci surgery robot lawsuit is nearing its conclusion ... According to Bloomberg.com, during closing statements yesterday, an attorney ... dealership, alleging the company wanted to tie sales and ... do all the training to keep control of surgeons, ...

Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Changing cancer's environment to halt its spread 2 Health News:Changing cancer's environment to halt its spread 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4

[0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors [0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Changing cancer's environment to halt its spread [0] Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial

... , ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: ... announced its financial results for the quarter and six months ended June 30, ... Revenues for the second quarter of 2009 increased 47% to $2.5 ... Gross profit for the second quarter of 2009 increased 96% ...

... NEWARK, N.J., Aug. 12 BioNeutral Group, Inc. ("BioNeutral") (OTC ... that ATS Labs using the EPA required AOAC Sporicidal Test with Ygiene(TM) ... over one million live Clostridium ... time frame - performance which is up to 75 times faster than ...

... With the recent increase in the tobacco tax, many Floridians ... times - do they pay the extra dollar per pack or ... The Florida Quitline (1-877-U-CAN-NOW) is here to help by offering free ... According to Kim Berfield, Deputy Secretary of the Florida Department of ...

... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...

... August 12 Fountain Healthy Aging,Inc. announced on August 12 ... Partners and Oak Resources Limited which provides the Company,with a ... the,agreement, Fountain has the right to draw down from the ... a term of 24 months. The,first tranche investment of $1,000,000 ...

... , WESTFIELD, Ind., Aug. 12 ... company for healthcare providers, announced the successful "Stage 6" designation ... hospital located in Silver City, New Mexico. maxIT assisted the ... IT consultants to support the implementation of several HIS modules. ...

VirtualScopics, Inc. Reports a Record Breaking Quarter BioNeutral's Ygiene(TM) Achieves World's Fastest Kill Time With a 100% Total Spore Eradication Verified In Independent Sporicidal/Sterilant Test The Time To Quit Is Now -- Free NRT Is Available Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition

Custom Pediatric Nebulizer Assembly W/Tubing...

... Patients over the age of 3 can choose ... STAR®. The same design principle applies to both:, ... and minimize aerosol output when the patient exhales ... optimum size to leave the nebulizer. The result ...

... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...

... Portex® medication nebulizers offer a spill-proof design ... to a 45° angle. All medical nebulizers ... wide variety of configurations are available., ... , ,Portex® medication nebulizers feature consistently ...

Medicine Products:

Pediatric Custom Nebulizers PARI LC STAR® Reusable Nebulizer Raindrop® Medication Nebulizer - Pediatric Aerosol Mask & Tubing 007767 Medication Nebulizer Kit